{"id":745096,"date":"2015-10-09T06:00:00","date_gmt":"2015-10-09T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/"},"modified":"2025-11-07T01:24:53","modified_gmt":"2025-11-07T06:24:53","slug":"keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA is Currently Approved in 39 Countries, including the United        States and throughout the European Union     <\/p>\n<\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the National Institute for Health and Care Excellence<br \/>\n      (NICE) of the United Kingdom (U.K.) has issued a draft recommendation,<br \/>\n      in the form of a Final Appraisal Determination (FAD), recommending<br \/>\n      KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab) as a first-line treatment option<br \/>\n      for adults with advanced melanoma.\n    <\/p>\n<p>\n      \u201cWe are pleased that the U.K. government has recognized the value of<br \/>\n      KEYTRUDA, and thank the government for its efforts to ensure that<br \/>\n      patients in the U.K. who have advanced melanoma have access to KEYTRUDA<br \/>\n      as soon as possible,\u201d said Deepak Khanna, senior vice president and<br \/>\n      regional president, Europe, MSD Oncology. \u201cMerck has demonstrated our<br \/>\n      strong commitment to ensuring KEYTRUDA would be available as quickly as<br \/>\n      possible to patients in the U.K., and around the world. Since the first<br \/>\n      approval in the United States just more than a year ago, KEYTRUDA has<br \/>\n      been approved in 39 countries, including throughout the European Union.\u201d\n    <\/p>\n<p>\n      In addition to today\u2019s NICE recommendation for KEYTRUDA as a first-line<br \/>\n      treatment option for adults with advanced melanoma, earlier this week<br \/>\n      NICE issued final guidance recommending KEYTRUDA for the treatment of<br \/>\n      advanced melanoma after disease progression with ipilimumab. KEYTRUDA<br \/>\n      was the first medicine available through the U.K. Early Access to<br \/>\n      Medicines Scheme (EAMS), which was introduced in the U.K. in 2014 to<br \/>\n      help patients with life-threatening or seriously debilitating conditions<br \/>\n      benefit from promising, innovative treatments before a European license<br \/>\n      has been granted.\n    <\/p>\n<p>\n      \u201cThe availability of KEYTRUDA for first-line use in patients will be<br \/>\n      welcomed by the melanoma community,\u201d said Gillian Nuttall, Founder of<br \/>\n      Melanoma UK.&nbsp;\u201cAdvanced melanoma is a very difficult disease to treat<br \/>\n      effectively and this treatment will give hope to many. We are delighted<br \/>\n      that patients will be able to access this treatment on the National<br \/>\n      Health Services and congratulate NICE on their swift decision making.\u201d\n    <\/p>\n<p>\n      Securing approvals for KEYTRUDA globally is a key element of Merck\u2019s<br \/>\n      efforts to ensure that the medicine is broadly available for eligible<br \/>\n      patients with advanced melanoma who are in need of new options around<br \/>\n      the world. To date, KEYTRUDA has been approved for the treatment of<br \/>\n      certain patients with advanced melanoma by regulatory authorities in the<br \/>\n      United States and the EU, as well as Australia, Canada, Israel, Macau,<br \/>\n      New Zealand, Peru, South Korea, Switzerland, and the United Arab<br \/>\n      Emirates (UAE). Additionally, the U.S. Food and Drug Administration<br \/>\n      (FDA) recently approved KEYTRUDA for certain patients with advanced<br \/>\n      non-small cell lung cancer (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fprescription-medicine-news%2Ffda-approves-keytruda-pembrolizumab-treatment-patients-metas&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=link&amp;index=1&amp;md5=09f2655d7dab3d129bc7b42b0f13b7c0\" rel=\"nofollow\">link<\/a>).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>(pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, and may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the U.S. at a dose of 2 mg\/kg administered as<br \/>\n      an intravenous infusion over 30 minutes every three weeks for the<br \/>\n      treatment of patients with unresectable or metastatic melanoma and<br \/>\n      disease progression following ipilimumab and, if BRAF V600 mutation<br \/>\n      positive, a BRAF inhibitor. KEYTRUDA is also indicated for the treatment<br \/>\n      of metastatic non-small cell lung cancer (NSCLC) whose tumors express<br \/>\n      PD-L1 as determined by an FDA-approved test with disease progression on<br \/>\n      or after platinum-containing chemotherapy. Patients with EGFR or ALK<br \/>\n      genomic tumor aberrations should have disease progression on<br \/>\n      FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.<br \/>\n      In the U.S., these indications are approved under accelerated approval<br \/>\n      based on tumor response rate and durability of response; an improvement<br \/>\n      in survival or disease-related symptoms has not yet been established.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Safety Information for KEYTRUDA in Advanced Melanoma Trial<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%)<br \/>\n      patients, respectively, receiving KEYTRUDA. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until<br \/>\n      metabolic control is achieved.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients, consisting of one case of Grade<br \/>\n      2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis<br \/>\n      with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients<br \/>\n      for changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial<br \/>\n      seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma, severe dermatitis including bullous pemphigoid, myasthenic<br \/>\n      syndrome, optic neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 9% of 411 patients.<br \/>\n      Adverse reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash<br \/>\n      (29%), decreased appetite (26%), constipation (21%), arthralgia (20%),<br \/>\n      and diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Selected Safety Information for KEYTRUDA in Metastatic NSCLC Trial<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 19 (3.5%) of 550 patients, including Grade 2<br \/>\n      (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis in patients<br \/>\n      receiving KEYTRUDA. Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Colitis occurred in 4 (0.7 %) of 550 patients, including Grade 2 (0.2%)<br \/>\n      or 3 (0.4%) colitis in patients receiving KEYTRUDA. Monitor patients for<br \/>\n      signs and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis occurred in patients receiving KEYTRUDA. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as indicated. Withhold KEYTRUDA<br \/>\n      for Grade 2 and withhold or discontinue for Grade 3 or Grade 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%). Hypothyroidism occurred in 38 (6.9%) of 550<br \/>\n      patients, including Grade 2 (5.5%) or 3 (0.2%). Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or Grade 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia or<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA and administer anti-hyperglycemics in<br \/>\n      patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Nephritis occurred in patients receiving KEYTRUDA. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or<br \/>\n      less following steroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      severe or Grade 3 immune-mediated adverse reaction that recurs and for<br \/>\n      any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, myasthenia gravis, bullous pemphigoid, and<br \/>\n      Guillain-Barr\u00e9 syndrome.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of patients.<br \/>\n      Serious adverse reactions occurred in 38% of patients. The most frequent<br \/>\n      serious adverse reactions reported in 2% or more of patients were<br \/>\n      pleural effusion, pneumonia, dyspnea, pulmonary embolism, and<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (44%), decreased appetite (25%), dyspnea (23%), and cough<br \/>\n      (29%).\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=1b6cc8841cbc0b4598304bfacaee62f7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=9855d236d0738000a5a29f3c6e05cc2c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=1fec5ffff741e3395a308f4cfb08bee5\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=6d554adb01812f118380793a8dfef484\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=250d4dd9abecce3a9c97b6bf86ea484f\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=c711a10dadd3b422e408a9aefa8ddd8e\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      ###\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=0f0dc108840ef3e006c5fd6ea78f3bce\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51198141&amp;newsitemid=20151009005277&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=4b36521cbf680966e1727f93e6d4a238\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151009005277r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>An Phan,        908-236-1130<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA \u00ae (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. \u201cWe are pleased that the U.K. government has recognized the value of KEYTRUDA, and thank the government for its efforts to ensure that patients in the U.K. who have advanced melanoma have access to KEYTRUDA as soon as possible,\u201d said Deepak Khanna, senior vice president and regional president, Europe, MSD Oncology. \u201cMerck has demonstrated our strong commitment to ensuring KEYTRUDA would be available as quickly as possible to patients in the U.K., and around the world. Since the first approval in the United<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745096","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA \u00ae (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. \u201cWe are pleased that the U.K. government has recognized the value of KEYTRUDA, and thank the government for its efforts to ensure that patients in the U.K. who have advanced melanoma have access to KEYTRUDA as soon as possible,\u201d said Deepak Khanna, senior vice president and regional president, Europe, MSD Oncology. \u201cMerck has demonstrated our strong commitment to ensuring KEYTRUDA would be available as quickly as possible to patients in the U.K., and around the world. Since the first approval in the United\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-10-09T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com","og_description":"KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA \u00ae (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. \u201cWe are pleased that the U.K. government has recognized the value of KEYTRUDA, and thank the government for its efforts to ensure that patients in the U.K. who have advanced melanoma have access to KEYTRUDA as soon as possible,\u201d said Deepak Khanna, senior vice president and regional president, Europe, MSD Oncology. \u201cMerck has demonstrated our strong commitment to ensuring KEYTRUDA would be available as quickly as possible to patients in the U.K., and around the world. Since the first approval in the United","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:53+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/","name":"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-10-09T06:00:00+00:00","dateModified":"2025-11-07T06:24:53+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-u-k-for-first-line-treatment-for-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"07e3373d-bf5e-4303-b37b-8c4b0c6350f2","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/KEYTRUDA-pembrolizumab-Receives-New-Draft-Recommendation-from-National-Institute-for-Health-and-Care-Excellence-NICE-in-UK-for-First--0L7H0.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745096\/revisions"}],"predecessor-version":[{"id":3674587,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745096\/revisions\/3674587"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745096"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}